

Massimo Federico

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4824946/publications.pdf>

Version: 2024-02-01

351
papers

24,389
citations

15495

65
h-index

8156

148
g-index

360
all docs

360
docs citations

360
times ranked

20261
citing authors

#	ARTICLE	IF	CITATIONS
1	Revised Response Criteria for Malignant Lymphoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 579-586.	0.8	4,061
2	Follicular Lymphoma International Prognostic Index. <i>Blood</i> , 2004, 104, 1258-1265.	0.6	1,552
3	Magnetic resonance imaging of the breast: Recommendations from the EUSOMA working group. <i>European Journal of Cancer</i> , 2010, 46, 1296-1316.	1.3	813
4	Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. <i>Lancet Oncology</i> , The, 2012, 13, 265-274.	5.1	790
5	Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. <i>Blood</i> , 2010, 116, 3724-3734.	0.6	784
6	EUROCORE-3: survival of cancer patients diagnosed 1990-1994 results and commentary. <i>Annals of Oncology</i> , 2003, 14, v61-v118.	0.6	638
7	Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2016, 374, 2419-2429.	13.9	629
8	Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project. <i>Journal of Clinical Oncology</i> , 2009, 27, 4555-4562.	0.8	613
9	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004, 103, 2474-2479.	0.6	549
10	EUROCORE-3 summary: cancer survival in Europe at the end of the 20th century. <i>Annals of Oncology</i> , 2003, 14, v128-v149.	0.6	400
11	Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1786-1794.	0.8	397
12	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011, 117, 3402-3408.	0.6	376
13	Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. <i>Journal of Clinical Oncology</i> , 2014, 32, 3490-3496.	0.8	358
14	Omitting Radiotherapy in Early Positron Emission Tomography-Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 1188-1194.	0.8	349
15	Multicenter Comparative Multimodality Surveillance of Women at Genetic-Familial High Risk for Breast Cancer (HIBCRI Study): Interim Results. <i>Radiology</i> , 2007, 242, 698-715.	3.6	324
16	Enteropathy-associated T-cell lymphoma: clinical and histological findings from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2011, 118, 148-155.	0.6	308
17	Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 1824-1833.	3.3	298
18	Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk) Tj ETQq0 0 Oa.gBT /Overbock 10 TF		

#	ARTICLE	IF	CITATIONS
19	Clinicopathologic Characteristics of Angioimmunoblastic T-Cell Lymphoma: Analysis of the International Peripheral T-Cell Lymphoma Project. <i>Journal of Clinical Oncology</i> , 2013, 31, 240-246.	0.8	287
20	ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009, 27, 805-811.	0.8	256
21	Stage at diagnosis is a key explanation of differences in breast cancer survival across Europe. <i>International Journal of Cancer</i> , 2003, 106, 416-422.	2.3	241
22	Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. <i>Journal of Clinical Oncology</i> , 2016, 34, 3618-3626.	0.8	231
23	R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLLO5 Trial Conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013, 31, 1506-1513.	0.8	223
24	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006, 107, 4643-4649.	0.6	217
25	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	0.6	193
26	Pattern of cancer risk in persons with AIDS in Italy in the HAART era. <i>British Journal of Cancer</i> , 2009, 100, 840-847.	2.9	176
27	ABVD Versus Modified Stanford V Versus MOPPEBVCAD With Optional and Limited Radiotherapy in Intermediate- and Advanced-Stage Hodgkin's Lymphoma: Final Results of a Multicenter Randomized Trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005, 23, 9198-9207.	0.8	167
28	Breast carcinoma survival in Europe and the United States. <i>Cancer</i> , 2004, 100, 715-722.	2.0	163
29	Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. <i>BMC Cancer</i> , 2007, 7, 230.	1.1	161
30	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet</i> , 2019, 394, 2271-2281.	6.3	155
31	PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study. <i>Blood</i> , 2016, 127, 1531-1538.	0.6	143
32	<i>KIT</i> and <i>PDGFRA</i> Mutations and the Risk of GI Stromal Tumor Recurrence. <i>Journal of Clinical Oncology</i> , 2015, 33, 634-642.	0.8	139
33	Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. <i>Lancet Haematology</i> , 2014, 1, e17-e27.	2.2	138
34	Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. <i>Blood</i> , 2018, 131, 1456-1463.	0.6	130
35	Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3019-3025.	0.8	129
36	The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLLO5 randomized trial of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2013, 24, 2108-2112.	0.6	124

#	ARTICLE	IF	CITATIONS
37	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012, 156, 346-353.	1.2	122
38	Hepatocellular Carcinoma: Trends of Incidence and Survival in Europe and the United States at the End of the 20th Century. <i>American Journal of Gastroenterology</i> , 2007, 102, 1661-1670.	0.2	121
39	Survival from rare cancer in adults: a population-based study. <i>Lancet Oncology</i> , The, 2006, 7, 132-140.	5.1	120
40	Childhood cancer survival in Europe. <i>Annals of Oncology</i> , 2003, 14, v119-v127.	0.6	119
41	Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. <i>Annals of Oncology</i> , 2004, 15, 1215-1221.	0.6	111
42	Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database. <i>Journal of Clinical Oncology</i> , 2012, 30, 3848-3853.	0.8	107
43	High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 2320-2325.	0.8	106
44	The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. <i>Cancer</i> , 2019, 125, 1507-1517.	2.0	106
45	Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial. <i>Clinical Cancer Research</i> , 2014, 20, 6398-6405.	3.2	94
46	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016, 34, 1175-1181.	0.8	94
47	HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. <i>Blood</i> , 2001, 98, 2752-2761.	0.6	92
48	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. <i>Human Molecular Genetics</i> , 2015, 24, 5345-5355.	1.4	91
49	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. <i>Haematologica</i> , 2018, 103, 1191-1197.	1.7	90
50	Hairy Cell Leukemia: A Clinical Review Based on 725 Cases of the Italian Cooperative Group (ICGHCL). <i>Leukemia and Lymphoma</i> , 1994, 13, 307-316.	0.6	86
51	Nonpegylated liposomal doxorubicin (Myocet, c) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EURO18 trial. <i>Annals of Oncology</i> , 2010, 21, 1492-1499.	0.6	81
52	Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis. <i>British Journal of Haematology</i> , 2013, 163, 40-46.	1.2	80
53	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , the, 2020, 7, e284-e294.	2.2	78
54	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. <i>Haematologica</i> , 2014, 99, 125-130.	1.7	77

#	ARTICLE	IF	CITATIONS
55	Reevaluation of prognostic significance of symptoms in Hodgkin's disease. <i>Cancer</i> , 1985, 56, 2874-2880.	2.0	76
56	Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. <i>Annals of Oncology</i> , 2011, 22, 1845-1858.	0.6	76
57	Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction. <i>British Journal of Cancer</i> , 2008, 99, 423-427.	2.9	75
58	The EUROCARE-3 database: methodology of data collection, standardisation, quality control and statistical analysis. <i>Annals of Oncology</i> , 2003, 14, v14-v27.	0.6	74
59	Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2006, 103, 195-198.	0.6	74
60	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012, 53, 581-588.	0.6	74
61	Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis. <i>Lancet Haematology</i> , 2018, 5, e359-e367.	2.2	74
62	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014, 55, 38-43.	0.6	72
63	High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma. <i>Cancer</i> , 2003, 97, 2748-2759.	2.0	71
64	Incidence of AIDS-Defining Cancers After AIDS Diagnosis Among People with AIDS in Italy, 1986-1998. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 84-90.	0.9	69
65	The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.	0.6	67
66	PDGFR expression in differential diagnosis between KIT-negative gastrointestinal stromal tumours and other primary soft-tissue tumours of the gastrointestinal tract. <i>Histopathology</i> , 2005, 46, 522-531.	1.6	66
67	High-dose therapy and autologous stem cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy: long-term results. <i>Haematologica</i> , 2009, 94, 146-148.	1.7	66
68	Variation in standard care for breast cancer across Europe: A EUROCARE-3 high resolution study. <i>European Journal of Cancer</i> , 2010, 46, 1528-1536.	1.3	66
69	Hodgkin disease survival in Europe and the U.S.. <i>Cancer</i> , 2006, 107, 352-360.	2.0	64
70	FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. <i>Annals of Oncology</i> , 2015, 26, 2155-2161.	0.6	63
71	The EUROCARE II study. <i>European Journal of Cancer</i> , 1998, 34, 2139-2153.	1.3	61
72	Classic Kaposi's sarcoma in Italy, 1985-1998. <i>British Journal of Cancer</i> , 2005, 92, 188-193.	2.9	58

#	ARTICLE	IF	CITATIONS
73	Therapeutic options in relapsed or refractory peripheral T-cell lymphoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1080-1088.	3.4	58
74	Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations. <i>European Journal of Human Genetics</i> , 2004, 12, 899-906.	1.4	55
75	Cancer prevalence in Central Europe: the EUROPREVAL Study. <i>Annals of Oncology</i> , 2003, 14, 313-322.	0.6	54
76	Development and Application of a Real-Time On-Line Blinded Independent Central Review of Interim Pet Scans to Determine Treatment Allocation in Lymphoma Trials. <i>Journal of Clinical Oncology</i> , 2009, 27, 2739-2741.	0.8	54
77	HODGKIN'S DISEASE PROGNOSIS: A DIRECTLY PREDICTIVE EQUATION. <i>Lancet, The</i> , 1988, 331, 675-679.	6.3	53
78	Decreasing incidence of gastric MALT lymphomas in the era of anti-Helicobacter pylori interventions: results from a population-based study on extranodal marginal zone lymphomas. <i>Annals of Oncology</i> , 2010, 21, 855-859.	0.6	53
79	Outcomes and Prognostic Factors in Angioimmunoblastic T cell Lymphoma: Final Report from the International TCell Project. <i>Blood</i> , 2021, 138, 213-220.	0.6	53
80	A prospective cohort study of patients with peripheral Tâ€cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	2.0	51
81	Activin, inhibin and the human breast. <i>Molecular and Cellular Endocrinology</i> , 2004, 225, 77-82.	1.6	50
82	HIV-1 Nef protects human-monocyte-derived macrophages from HIV-1-induced apoptosis. <i>Experimental Cell Research</i> , 2006, 312, 890-900.	1.2	50
83	Prevalence ofBRCA1 genomic rearrangements in a large cohort of Italian breast and breast/ovarian cancer families without detectableBRCA1 andBRCA2 point mutations. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 791-797.	1.5	50
84	Breast cancer screening in women at increased risk according to different family histories: an update of the Modena Study Group experience. <i>BMC Cancer</i> , 2006, 6, 210.	1.1	49
85	Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. <i>Hematological Oncology</i> , 2007, 25, 189-197.	0.8	49
86	Peripheral T cell lymphoma, not otherwise specified (PTCLâ€NOS). A new prognostic model developed by the International T cell Project Network. <i>British Journal of Haematology</i> , 2018, 181, 760-769.	1.2	49
87	Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study. <i>Blood</i> , 2018, 131, 2449-2453.	0.6	49
88	Detection of Circulating Tumor Cells by Reverse Transcriptase Polymerase Chain Reaction of Maspin in Patients With Breast Cancer Undergoing Conventional-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2000, 18, 1914-1920.	0.8	48
89	Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. <i>Journal of Clinical Oncology</i> , 2002, 20, 638-646.	0.8	48
90	Comparison of prognostic models in patients with advanced Hodgkin disease. <i>Cancer</i> , 2001, 91, 1467-1478.	2.0	47

#	ARTICLE	IF	CITATIONS
91	Weight Gain in Women with Breast Cancer Treated with Adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil. Analysis of Resting Energy Expenditure and Body Composition. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 267-273.	1.1	47
92	Long-Term Follow-Up Analysis of HD9601 Trial Comparing ABVD Versus Stanford V Versus MOPP/EBV/CAD in Patients With Newly Diagnosed Advanced-Stage Hodgkin's Lymphoma: A Study From the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011, 29, 4227-4233.	0.8	47
93	Cancer incidence in eastern Libya: The first report from the Benghazi Cancer Registry, 2003. <i>International Journal of Cancer</i> , 2007, 120, 392-397.	2.3	46
94	Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature. <i>Autoimmunity Reviews</i> , 2014, 13, 132-137.	2.5	45
95	Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas. <i>American Journal of Hematology</i> , 2020, 95, 151-155.	2.0	43
96	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléculas Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 53-57.	0.6	42
97	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007, 110, 121-128.	2.0	41
98	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018, 183, 755-765.	1.2	41
99	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas. <i>Cancer</i> , 2004, 101, 1601-1608.	2.0	40
100	Elongation Factor 1 alpha interacts with phospho-Akt in breast cancer cells and regulates their proliferation, survival and motility. <i>Molecular Cancer</i> , 2009, 8, 58.	7.9	39
101	Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients. <i>Mayo Clinic Proceedings</i> , 2015, 90, 756-764.	1.4	39
102	Prognostic relevance of serum λ 2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007, 92, 1482-1488.	1.7	38
103	Indications for breast magnetic resonance imaging. Consensus document "Attualità in senologia", Florence 2007. <i>Radiologia Medica</i> , 2008, 113, 1085-1095.	4.7	38
104	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017, 102, 1748-1757.	1.7	38
105	T-Cell Lymphomas in South America and Europe. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 42-47.	0.7	38
106	Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 37, 13-25.	2.0	37
107	Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997-2001). <i>British Journal of Cancer</i> , 2006, 95, 1265-1268.	2.9	37
108	Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis. <i>European Journal of Haematology</i> , 2006, 77, 387-394.	1.1	37

#	ARTICLE	IF	CITATIONS
109	The oral protein-kinase C inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. <i>Leukemia and Lymphoma</i> , 2008, 49, 1374-1383.	0.6	37
110	Identification of Protein Clusters Predictive of Response to Chemotherapy in Breast Cancer Patients. <i>Journal of Proteome Research</i> , 2009, 8, 4916-4933.	1.8	37
111	Screening patterns within organized programs and survival of Italian women with invasive cervical cancer. <i>Preventive Medicine</i> , 2013, 57, 220-226.	1.6	37
112	Twelve Years Experience with High-Dose Therapy and Autologous Stem Cell Transplantation for High-Risk Hodgkin's Disease Patients in First Remission After MOPP/ABVD Chemotherapy. <i>Leukemia and Lymphoma</i> , 1996, 21, 63-70.	0.6	36
113	Relevance of Stereotyped B-Cell Receptors in the Context of the Molecular, Cytogenetic and Clinical Features of Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2011, 6, e24313.	1.1	36
114	Relative and disease-free survival for breast cancer in relation to subtype: a population-based study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1569-1577.	1.2	36
115	Early-stage diffuse large B cell lymphoma of the head and neck: clinico-biological characterization and 18Åyear follow-up of 488 patients (IELSG 23 study). <i>Annals of Hematology</i> , 2014, 93, 221-231.	0.8	36
116	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e66-e68.	1.7	36
117	Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. <i>Hematological Oncology</i> , 2017, 35, 561-566.	0.8	36
118	Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study. <i>Haematologica</i> , 2008, 93, 1335-1342.	1.7	35
119	A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women. <i>Annals of Oncology</i> , 2014, 25, 57-63.	0.6	35
120	Changes in cervical cancer incidence following the introduction of organized screening in Italy. <i>Preventive Medicine</i> , 2015, 75, 56-63.	1.6	35
121	Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. <i>Supportive Care in Cancer</i> , 2004, 12, 446-453.	1.0	34
122	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 729-739.	0.8	34
123	Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. <i>BMC Cancer</i> , 2010, 10, 90.	1.1	33
124	Impact of diabetes on overall and cancer-specific mortality in colorectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 1303-1310.	1.2	33
125	EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014048.	0.5	33
126	Prognostic value of morphology and hormone receptor status in breast cancer – a population-based study. <i>British Journal of Cancer</i> , 2004, 91, 1263-1268.	2.9	32

#	ARTICLE	IF	CITATIONS
127	Ovarian Cancer: Can Proteomics Give New Insights for Therapy and Diagnosis?. International Journal of Molecular Sciences, 2013, 14, 8271-8290.	1.8	32
128	BRCA1 mutations and clinicopathological features in a sample of Italian women with early-onset breast cancer. European Journal of Cancer, 2000, 36, 2083-2089.	1.3	31
129	Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials. Cancer Medicine, 2020, 9, 6565-6575.	1.3	29
130	Serum albumin in Hodgkin's disease. Cancer, 1985, 55, 389-393.	2.0	28
131	Survival in Adult Italian Cancer Patients, 1978-1989. Tumori, 1997, 83, 39-425.	0.6	28
132	Variations in the Survival of Adult Cancer Patients in Italy. Tumori, 1997, 83, 497-504.	0.6	28
133	Risk of Second Cancer in Patients With Hairy Cell Leukemia: Long-Term Follow-Up. Journal of Clinical Oncology, 2002, 20, 638-646.	0.8	28
134	Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma. Cancer, 2003, 98, 2393-2401.	2.0	28
135	Electronic availability of EUROCARE-3 data: a tool for further analysis. Annals of Oncology, 2003, 14, v150-v155.	0.6	28
136	CLIP1: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11). Annals of Hematology, 2011, 90, 401-408.	0.8	28
137	Residual tumour volumes and grey zones after external beam radiotherapy (with or without Tj ETQq1 1 0.784314 1.0 BT /Overlock 10 Tf	1.0	28
138	Twenty-years experience with <i>de novo</i> metastatic breast cancer. International Journal of Cancer, 2015, 137, 1417-1426.	2.3	28
139	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. Leukemia, 2016, 30, 1440-1443.	3.3	28
140	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. American Journal of Hematology, 2013, 88, 24-31.	2.0	27
141	Cancer incidence, mortality, and survival in Eastern Libya: updated report from the Benghazi Cancer Registry. Annals of Epidemiology, 2015, 25, 564-568.	0.9	27
142	Increased Incidence of Breast Cancer in Postmenopausal Women with High Body Mass Index at the Modena Screening Program. Journal of Breast Cancer, 2016, 19, 283.	0.8	27
143	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 193-200.	0.2	27
144	Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. , 2000, 27, 130-135.		26

#	ARTICLE	IF	CITATIONS
145	An oncologist-based model of cancer genetic counselling for hereditary breast and ovarian cancer. <i>Annals of Oncology</i> , 2004, 15, 726-732.	0.6	26
146	Regional inequalities in cancer care persist in Italy and can influence survival. <i>Cancer Epidemiology</i> , 2012, 36, 541-547.	0.8	26
147	Identification of families with hereditary breast and ovarian cancer for clinical and mammographic surveillance: the Modena Study Group proposal. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 213-221.	1.1	25
148	A multicenter retrospective clinical study of CD5/CD10 α -negative chronic B cell leukemias. <i>American Journal of Hematology</i> , 2008, 83, 349-354.	2.0	25
149	Risk of Second Primary Malignancy in Breast Cancer Survivors: A Nested Population-Based Case-Control Study. <i>Journal of Breast Cancer</i> , 2015, 18, 378.	0.8	25
150	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015, 56, 3281-3287.	0.6	25
151	Single agents vs combination chemotherapy in relapsed and refractory peripheral T α -cell lymphoma: Results from the comprehensive oncology measures for peripheral T α -cell lymphoma treatment (COMPLETE) registry. <i>American Journal of Hematology</i> , 2019, 94, 641-649.	2.0	25
152	The impact of organised screening programmes on the stage-specific incidence of breast cancer in some Italian areas. <i>European Journal of Cancer</i> , 2003, 39, 1776-1782.	1.3	24
153	The Role of Anthracyclines in Combination Chemotherapy for the Treatment of Follicular Lymphoma: Retrospective Study of the Intergruppo Italiano Linfomi 761 Cases. <i>Leukemia and Lymphoma</i> , 2003, 44, 1911-1917.	0.6	24
154	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. <i>Leukemia Research</i> , 2013, 37, 619-623.	0.4	24
155	Follicular lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 54-59.	0.7	24
156	Cancer Patient Survival in the Elderly in Italy. <i>Tumori</i> , 1997, 83, 490-496.	0.6	23
157	Treatment of Indolent B-Cell Nonfollicular Lymphomas: Final Results of the LL01 Randomized Trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003, 21, 1459-1465.	0.8	23
158	Prognosis of screen-detected breast cancers: results of a population based study. <i>BMC Cancer</i> , 2006, 6, 17.	1.1	23
159	High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study. <i>Leukemia and Lymphoma</i> , 2011, 52, 823-832.	0.6	23
160	Protein expression patterns associated with advanced stage ovarian cancer. <i>Electrophoresis</i> , 2011, 32, 1992-2003.	1.3	23
161	Different Expressivity of BRCA1 and BRCA2: Analysis of 179 Italian Pedigrees with Identified Mutation. <i>Breast Cancer Research and Treatment</i> , 2003, 81, 71-79.	1.1	22
162	Colon cancer prevalence and estimation of differing care needs of colon cancer patients. <i>Annals of Oncology</i> , 2004, 15, 1136-1142.	0.6	22

#	ARTICLE	IF	CITATIONS
163	In situ breast cancer: Incidence trend and organised screening programmes in Italy. <i>European Journal of Cancer</i> , 2005, 41, 1045-1050.	1.3	22
164	Screen-detected vs clinical breast cancer: the advantage in the relative risk of lymph node metastases decreases with increasing tumour size. <i>British Journal of Cancer</i> , 2005, 92, 156-161.	2.9	21
165	Cancer incidence in people with residential exposure to a municipal waste incinerator: An ecological study in Modena (Italy), 1991-2005. <i>Waste Management</i> , 2010, 30, 1362-1370.	3.7	21
166	Acceptability and Adherence in a Chemoprevention Trial among Women at Increased Risk for Breast Cancer Attending the Modena Familial Breast and Ovarian Cancer Center (Italy). <i>Breast Journal</i> , 2013, 19, 10-21.	0.4	21
167	Outcome of transformed follicular lymphoma worsens according to the timing of transformation and to the number of previous therapies. A retrospective multicenter study on behalf of Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2019, 185, 713-717.	1.2	21
168	Positron-emission tomography-based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. <i>European Journal of Cancer</i> , 2020, 126, 78-90.	1.3	21
169	The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Bone Marrow Transplantation</i> , 2006, 37, 283-288.	1.3	20
170	Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 367-373.	0.6	20
171	Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Supportive Care in Cancer</i> , 2011, 19, 1505-1510.	1.0	20
172	Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>British Journal of Haematology</i> , 2015, 169, 544-551.	1.2	20
173	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq1 1 0,784314 rgBT /Oveldo	0.4	20
174	Incidence of primary liver cancer in Italy between 1988 and 2002: An age-period-cohort analysis. <i>European Journal of Cancer</i> , 2008, 44, 285-292.	1.3	19
175	Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study. <i>Hematological Oncology</i> , 2017, 35, 630-636.	0.8	19
176	Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 549-549.	0.6	19
177	Precision medicine in diffuse large B-cell lymphoma: hitting the target. <i>Haematologica</i> , 2015, 100, 989-93.	1.7	19
178	ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL). <i>Leukemia and Lymphoma</i> , 1995, 17, 313-320.	0.6	18
179	Cancer prevalence in Northern Europe: the EUROPREVAL study. <i>Annals of Oncology</i> , 2003, 14, 946-957.	0.6	18
180	Anthracyclines: A Cornerstone in the Management of Non-Hodgkin's Lymphoma. <i>Hematology Reports</i> , 2011, 3, e4.	0.3	18

#	ARTICLE	IF	CITATIONS
181	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 12-25.	0.6	18
182	Distribution of Second Primary Malignancies Suggests a Bidirectional Effect Between Breast and Endometrial Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 1358-1363.	1.2	17
183	Prognosis of follicular lymphomas. <i>Hematological Oncology</i> , 2006, 24, 64-72.	0.8	16
184	Tumour burden predicts treatment resistance in patients with early unfavourable or advanced stage Hodgkin lymphoma treated with ABVD and radiotherapy. <i>Hematological Oncology</i> , 2012, 30, 194-199.	0.8	16
185	Dismal outcome of t�cell lymphoma patients failing first�line treatment: results of a population�based study from the Modena Cancer Registry. <i>Hematological Oncology</i> , 2015, 33, 147-151.	0.8	16
186	Long Term Results of Interferon Treatment in Hairy Cell Leukemia Italian Cooperative Group of Hairy Cell Leukemia (ICGHCL). <i>Leukemia and Lymphoma</i> , 1994, 14, 457-464.	0.6	15
187	Cancer profile in Eastern Libya: incidence and mortality in the year 2004. <i>Annals of Oncology</i> , 2010, 21, 1924-1926.	0.6	15
188	External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2013, 119, 1177-1185.	2.0	15
189	Fertility in female survivors of Hodgkin's lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2011, 34, 48-53.	0.7	15
190	In Vitro Drug Testing of Ovarian Cancer Using the Human Tumor Colony-Forming Assay: Comparison of in Vitro Response and Clinical Outcome. <i>Gynecologic Oncology</i> , 1994, 55, S156-S163.	0.6	14
191	Stage-specific incidence of breast cancer before the beginning of organized screening programs in Italy. <i>Cancer Causes and Control</i> , 2002, 13, 65-71.	0.8	14
192	MOPPEBVCAD Chemotherapy with Limited and Conditioned Radiotherapy in Advanced Hodgkin's Lymphoma: 10-Year Results, Late Toxicity, and Second Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 529-535.	3.2	14
193	Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): Results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi. <i>Leukemia and Lymphoma</i> , 2006, 47, 473-479.	0.6	14
194	Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 62-68.	0.6	14
195	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O�CLL1�GISL study. <i>American Journal of Hematology</i> , 2014, 89, 743-750.	2.0	14
196	Safety Profile and Clinical Response To MEDI-551, a Humanized Monoclonal Anti-CD19, In a Phase 1/2 Study In Adults With Relapsed Or Refractory Advanced B-Cell Malignancies. <i>Blood</i> , 2013, 122, 1810-1810.	0.6	14
197	Estimated and Observed Cancer Incidence in Italy: A Validation Study. <i>Tumori</i> , 2007, 93, 387-391.	0.6	13
198	Prognostic factors in low-grade non-Hodgkin lymphomas. <i>Current Hematologic Malignancy Reports</i> , 2009, 4, 202-210.	1.2	13

#	ARTICLE	IF	CITATIONS
199	R-Roscovitine (Seliciclib) prevents DNA damage-induced cyclin A1 upregulation and hinders non-homologous end-joining (NHEJ) DNA repair. <i>Molecular Cancer</i> , 2010, 9, 208.	7.9	13
200	Lymph node evaluation in stage IIA colorectal cancer and its impact on patient prognosis: A population-based study. <i>Acta Oncologica</i> , 2013, 52, 1682-1690.	0.8	13
201	Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 507-513.	0.2	13
202	Combination of rituximab and nonpegylated liposomal doxorubicin (<scp>Râ€NPLD</scp>) as frontâ€line therapy for aggressive nonâ€Hodgkin lymphoma (<scp>NHL</scp>) in patients 80Âyears of age or older: a singleâ€center retrospective study. <i>Hematological Oncology</i> , 2018, 36, 44-48.	0.8	13
203	Incidence Clinical Characteristics and Survival of Non Splenic Marginal Zone Lymphomas: A Population Based Study from a Cancer Registry in Northern Italy. <i>Blood</i> , 2008, 112, 3753-3753.	0.6	13
204	Brentuximab vedotin followed by ABVD +/â radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study. <i>Haematologica</i> , 2016, 101, e139-e141.	1.7	12
205	Detection and Quantitation in Rat Tissues of the Superparamagnetic Magnetic Resonance Contrast Agent Dextran Magnetite as Demonstrated by Electron Spin Resonance Spectroscopy. <i>Investigative Radiology</i> , 1992, 27, 450-455.	3.5	11
206	Evaluation of Quality of Life in Patients with Metastatic Colorectal Cancer Treated with Capecitabine. <i>Clinical Colorectal Cancer</i> , 2008, 7, 126-133.	1.0	11
207	International collaborations in cancer control and the Third International Cancer Control Congress. <i>Tumori</i> , 2009, 95, 579-596.	0.6	11
208	Chemoresistance As a Function of the Pretherapy Tumor Burden and the Chemotherapy Regimen Administered: Differences Observed With 2 Current Chemotherapy Regimens for Advanced Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 396-402.	0.2	11
209	Risk factors for impaired gonadal function in female Hodgkin lymphoma survivors: final analysis of a retrospective multicenter joint study from Italian and Brazilian Institutions. <i>Hematological Oncology</i> , 2013, 31, 72-78.	0.8	11
210	Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12*. <i>Leukemia and Lymphoma</i> , 2017, 58, 64-69.	0.6	11
211	EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic. <i>HemaSphere</i> , 2021, 5, e529.	1.2	11
212	Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study. <i>Haematologica</i> , 2022, 107, 2675-2684.	1.7	11
213	New clinical criteria for the assessment of liver involvement in Hodgkin's disease. <i>European Journal of Cancer & Clinical Oncology</i> , 1982, 18, 1243-1249.	0.9	10
214	Human lymphoblastoid interferon as initial therapy in hairy cell leukaemia: a multicentre study in non-splenectomized patients. <i>British Journal of Haematology</i> , 1989, 72, 54-56.	1.2	10
215	Effects of Thymostimulin with Combination Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995, 18, 8-14.	0.6	10
216	Prognostic tools in follicular lymphomas. <i>Expert Review of Hematology</i> , 2009, 2, 549-562.	1.0	10

#	ARTICLE	IF	CITATIONS
217	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISEL). <i>Annals of Hematology</i> , 2011, 90, 323-330.	0.8	10
218	What has happened to VBM (vinblastine, bleomycin, and methotrexate) chemotherapy for early-stage Hodgkin lymphoma?. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 18-24.	2.0	10
219	Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter OCLL1-GISEL study. <i>American Journal of Hematology</i> , 2013, 88, 539-544.	2.0	10
220	Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. <i>International Journal of Cancer</i> , 2013, 132, E58-65.	2.3	10
221	Tumour burden at diagnosis as the main clinical predictor of cell resistance in patients with early stage, favourable Hodgkin lymphoma treated with VBM chemotherapy plus radiotherapy. <i>Hematological Oncology</i> , 2013, 31, 151-155.	0.8	10
222	Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. <i>Leukemia and Lymphoma</i> , 2014, 55, 988-998.	0.6	10
223	The Value and Relevance of the T Cell Lymphoma Registries and International Collaborations: the Case of COMPLETE and the T-Cell Project. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 448-455.	1.2	10
224	Increasing Interdependency of Prognosis- and Therapy-Related Factors in Hodgkin's Disease. <i>Acta Haematologica</i> , 1989, 81, 34-40.	0.7	9
225	Should alpha interferon be used as primary treatment for hairy cell leukemia?. <i>Leukemia Research</i> , 1991, 15, 419-426.	0.4	9
226	A pilot study on the use of the proMACE-cytaBOM regimen as a first-line treatment of advanced follicular non-Hodgkin's lymphoma. , 1997, 79, 1234-1240.		9
227	Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISEL) Prospective Trial. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 138-144.	1.4	9
228	Differences in Stage and Treatment of Breast Cancer across Italy Point to Inequalities in access to and Availability of Proper Care. <i>Tumori</i> , 2012, 98, 204-209.	0.6	9
229	Outcome Evaluation in Pre-Trastuzumab Era between Different Breast Cancer Phenotypes: A Population-Based Study on Italian Women. <i>Tumori</i> , 2012, 98, 743-750.	0.6	9
230	BEACOPP or no BEACOPP?. <i>Lancet Oncology</i> , The, 2013, 14, e487-e488.	5.1	9
231	The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. <i>Leukemia Research</i> , 2013, 37, 943-947.	0.4	9
232	Resources-Stratified Guidelines for Classical Hodgkin Lymphoma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 1783.	1.2	9
233	Biomarker Quality Assurance (QA) Findings From the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry. <i>Blood</i> , 2012, 120, 4263-4263.	0.6	9
234	Bone marrow uptake of liposome-entrapped spin label after liver blockade with empty liposomes. <i>Magnetic Resonance in Medicine</i> , 1989, 10, 418-425.	1.9	8

#	ARTICLE	IF	CITATIONS
235	Bone marrow infiltration in hairy cell leukemia after interferon therapy detected by magnetic resonance imaging. <i>European Journal of Cancer & Clinical Oncology</i> , 1989, 25, 209-213.	0.9	8
236	Anaplastic large cell lymphoma (CD30+/Ki-1+). Analysis of 35 cases followed at GISL centres. <i>European Journal of Cancer</i> , 1995, 31, 1763-1767.	1.3	8
237	SPECIAL DEPARTMENTS. <i>Journal of Clinical Oncology</i> , 2000, 18, 3196-3197.	0.8	8
238	Prospective Study of Indolent Non-follicular Non-Hodgkin's Lymphoma: Validation of Gruppo Italiano Per Lo Studio Dei Linfomi (GISL) Prognostic Criteria for Watch and Wait Policy. <i>Leukemia and Lymphoma</i> , 2002, 43, 1933-1938.	0.6	8
239	The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006, 76, 217-229.	1.1	8
240	Tumor burden in Hodgkin's lymphoma can be reliably estimated from a few staging parameters. <i>Oncology Reports</i> , 2012, 28, 815-820.	1.2	8
241	Prognosis and treatment of micrometastatic breast cancer sentinel lymph node: A population-based study. <i>Journal of Surgical Oncology</i> , 2012, 106, 399-405.	0.8	8
242	Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 744-748.	0.2	8
243	Detection of Bone Marrow Involvement in Patients with Cancer. <i>Tumori</i> , 1989, 75, 90-96.	0.6	7
244	Changes in breast cancer incidence and stage distribution in Modena, Italy: the effect of a mammographic screening program. <i>Cancer Causes and Control</i> , 2002, 13, 729-734.	0.8	7
245	Prevalence and prognostic significance of sMUC-1 levels in plasma cell dyscrasias. <i>British Journal of Haematology</i> , 2003, 121, 772-774.	1.2	7
246	Italian family with two independent mutations: 3358T/A in BRCA1 and 8756delA in BRCA2 genes. <i>European Journal of Human Genetics</i> , 2003, 11, 210-214.	1.4	7
247	Role of interferon-alpha administration after 2-deoxycoformycin in the treatment of hairy cell leukemia patients. <i>European Journal of Haematology</i> , 2006, 77, 109-113.	1.1	7
248	ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. <i>Annals of Oncology</i> , 2008, 19, 763-768.	0.6	7
249	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter Oâ€œscp>CLL</scp> 1â€œscp>GISL</scp> study. <i>European Journal of Haematology</i> , 2016, 96, 36-45.	1.1	7
250	G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony-stimulating factors (G-CSF) as observed in clinical practice in Italy. <i>Medical Oncology</i> , 2016, 33, 139.	1.2	7
251	The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective International T-Cell Project. <i>Haematologica</i> , 2019, 104, e178.2-e178.	1.7	7
252	Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE): First Detailed Report of Primary Treatment. <i>Blood</i> , 2012, 120, 1614-1614.	0.6	7

#	ARTICLE	IF	CITATIONS
253	A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12. Blood, 2013, 122, 155-155.	0.6	7
254	Bleomycin, Epidoxorubicin, Cyclophosphamide, Vincristine and Prednisone (BACOP) in Patients with Follicular Non-Hodgkin's Lymphoma: Results of a Prospective, Multicenter Study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISTL). Leukemia and Lymphoma, 2002, 43, 1795-1801.	0.6	6
255	Defining the best cutoff value for lymphopenia in diffuse large B cell lymphoma treated with immunochemotherapy. British Journal of Haematology, 2014, 167, 133-136.	1.2	6
256	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. Haematologica, 2015, 100, 517-524.	1.7	6
257	Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma. Hematological Oncology, 2021, 39, 293-303.	0.8	6
258	Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL). Blood, 2014, 124, 4434-4434.	0.6	6
259	Differences in stage and treatment of breast cancer across Italy point to inequalities in access to and availability of proper care. Tumori, 2012, 98, 204-9.	0.6	6
260	The burden of rare cancers in Italy: the surveillance of rare cancers in Italy (RITA) project. Tumori, 2012, 98, 550-8.	0.6	6
261	Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women. Tumori, 2012, 98, 743-50.	0.6	6
262	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide. British Journal of Haematology, 2003, 123, 747-748.	1.2	5
263	The role of dose size in a chemotherapy regimen (ProMECE-CytaBOM) for the first-line treatment of large B-cell lymphomas: a randomized trial by the Gruppo Italiano Studio Linfomi (GISTL). Annals of Oncology, 2006, 17, 676-682.	0.6	5
264	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphoma. Oncology Reports, 2009, 21, 1029-35.	1.2	5
265	Advances in Treatment of Follicular Lymphoma. Cancer Journal (Sudbury, Mass), 2020, 26, 231-240.	1.0	5
266	MEDI-551, a Humanized Monoclonal Anti-CD19, in Adults with Relapsed or Refractory Advanced B-Cell Malignancies: Results From a Phase 1/2 Study. Blood, 2012, 120, 3677-3677.	0.6	5
267	R-CVP versus R-CHOP versus R-FM as first-line therapy for advanced-stage follicular lymphoma: Final results of FOLL05 trial from the Fondazione Italiana Linfomi (FIL).. Journal of Clinical Oncology, 2012, 30, 8006-8006.	0.8	5
268	A pilot phase II study with brentuximab vedotin followed by ABVD in patients with previously untreated Hodgkin lymphoma: A preliminary report.. Journal of Clinical Oncology, 2014, 32, 8507-8507.	0.8	5
269	The Early- and Intermediate-Term Toxicity to Primitive Hematopoietic Progenitor Cells of Three Chemotherapy Regimens for Advanced Hodgkin Lymphoma. Clinical Lymphoma and Myeloma, 2009, 9, 425-429.	1.4	4
270	Use of 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography in patients with Hodgkin lymphoma in daily practice: a population-based study from Northern Italy. Leukemia and Lymphoma, 2011, 52, 1689-1696.	0.6	4

#	ARTICLE	IF	CITATIONS
271	An Increased Number of Individuals with Clinically Recognized Monoclonal B-Cell Lymphocytosis Characterizes a Recent Database of Chronic Lymphocytic Leukemia Rai Stage 0. <i>Acta Haematologica</i> , 2012, 127, 149-151.	0.7	4
272	Prophylactic Surgery to Reduce the Risk of Developing Breast Cancer: Issues and Clinical Implications. <i>Current Women's Health Reviews</i> , 2012, 8, 94-103.	0.1	4
273	A case of skeletal and bone marrow metastases from breast cancer treated with eribulin mesylate. <i>Future Oncology</i> , 2013, 9, 1437-1442.	1.1	4
274	Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindi et al, and S. Kothari et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 2853-2854.	0.8	4
275	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 439-445.	0.8	4
276	Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma. <i>European Journal of Cancer</i> , 2021, 157, 132-139.	1.3	4
277	Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study. <i>Blood</i> , 2007, 110, 1293-1293.	0.6	4
278	Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: Final Results of the Randomized Phase III NCIC CTG Study LY12. <i>Blood</i> , 2012, 120, 745-745.	0.6	4
279	CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8552-8552.	0.8	4
280	Diagnosis, prevention and treatment of central nervous system involvement in peripheral t-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 167, 103496.	2.0	4
281	Hodgkin's disease. <i>Clinical Imaging</i> , 2004, 28, 239-244.	0.8	3
282	Estimating survival in newly diagnosed cancer patients: Use of computer simulations to evaluate performances of different approaches in a wide range of scenarios. <i>Statistics in Medicine</i> , 2008, 27, 2145-2158.	0.8	3
283	Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. <i>Leukemia Research</i> , 2010, 34, e217-e218.	0.4	3
284	Role of glutathione-s-transferase (gst) polymorphisms in patients with advanced hodgkin lymphoma: results from the hd2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012, 53, 406-410.	0.6	3
285	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.	2.0	3
286	Reply to H.J.A. Adams et al and E. Laffon et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 920-923.	0.8	3
287	<i>BRCA</i> mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees. <i>Cancer Biology and Medicine</i> , 2021, 18, 470-476.	1.4	3
288	Evaluation of Quality of Biomarker Data Capture by Peripheral Sites in an International, Cooperative Study: Analysis of 104 Cases From the T-Cell Project.. <i>Blood</i> , 2012, 120, 2650-2650.	0.6	3

#	ARTICLE	IF	CITATIONS
289	MD Anderson Cancer Center (MDACC) Score Adds Prognostic Information To The Distinction Between High COUNT Monoclonal B-CELL Lymphocytosis (HC-MBL) and RAI STAGE 0 Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013, 122, 4172-4172.	0.6	3
290	Double Hit Lymphoma Diagnosis and Treatment in Europe – A Cross-Sectional Survey of Clinical Practice by the EHA Lymphoma Working Party (EHA LyG). <i>HemaSphere</i> , 2020, 4, e481.	1.2	3
291	Prevention of Cisplatin-Induced Vomiting in Patients with Cancer. A Pilot Study with a Multiagent Protocol. <i>Tumori</i> , 1990, 76, 278-281.	0.6	2
292	Preliminary Analysis of Clinical Characteristics of Patients Enrolled in the HD01 Protocol: A Randomised Trial of High Dose Therapy and Autologous Stem Cell Transplantation Versus Conventional Therapy for Patients with Advanced Hodgkin's Disease Responding to First Line Therapy. <i>Leukemia and Lymphoma</i> , 1995, 15, 63-66.	0.6	2
293	Comment on “Cancer genetic counselling” by P. Mandich et al. (<i>Ann Oncol</i> 2005; 16: 171). <i>Annals of Oncology</i> , 2005, 16, 1208-1209.	0.6	2
294	T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2009, 31, .	0.7	2
295	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010, 51, 422-429.	0.6	2
296	Case Studies of Elderly Patients with Non-Hodgkin's Lymphoma. <i>Hematology Reports</i> , 2011, 3, e7.	0.3	2
297	MRI in high risk women: benefits and problems. <i>European Journal of Radiology</i> , 2012, 81, S19-S20.	1.2	2
298	Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries. <i>Breast</i> , 2013, 22, 476-481.	0.9	2
299	Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2016, 38, 247-251.	0.7	2
300	Time to publish: challenging the performance of cooperative group lymphoma trials. <i>Lancet Haematology</i> , 2017, 4, e8-e10.	2.2	2
301	Absolute monocyte count at diagnosis could improve the prognostic role of early ^{18}F -FDG-PET in classical Hodgkin lymphoma patients. <i>British Journal of Haematology</i> , 2018, 180, 600-602.	1.2	2
302	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1011-1014.	1.2	2
303	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin's Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). <i>Blood</i> , 2013, 122, 3049-3049.	0.6	2
304	Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial. <i>Blood</i> , 2016, 128, 184-184.	0.6	2
305	Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (Gruppo Italiano Studio Linfomi) Trial. <i>Blood</i> , 2010, 116, 1360-1360.	0.6	2
306	Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 12068-12068.	0.8	2

#	ARTICLE	IF	CITATIONS
307	End of induction positron emission tomography complete response (PET- CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 198, 333-337.	1.2	2
308	Splenosis peritonei. <i>British Journal of Haematology</i> , 2003, 123, 378-378.	1.2	1
309	Radiological Screening Programs for Women at High Risk of Developing Breast Cancer. <i>Current Women's Health Reviews</i> , 2012, 8, 72-85.	0.1	1
310	MRI before initial surgery outside of clinical trials: the real world!. <i>European Journal of Radiology</i> , 2012, 81, S21-S23.	1.2	1
311	Collective evidence supports neutrality of BRCA1 V1687I, a novel sequence variant in the conserved THV motif of the first BRCT repeat. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 435-441.	1.1	1
312	Reply to T.P. Vassilakopoulos et al. <i>Journal of Clinical Oncology</i> , 2016, 34, 3585-3586.	0.8	1
313	Hodgkin Lymphoma: Comments on ESMO Clinical Practice Guidelines. <i>HemaSphere</i> , 2020, 4, e458.	1.2	1
314	Cancer Stem Cells and Microenvironment. , 2010, , 169-185.		1
315	R-CHOP vs R-MiniCEOP in Elderly Patients with Diffuse Large B-Cell Lymphoma (B-DLCL) Prospectively Selected by a Multidimensional Evaluation Scale: Preliminary Results of a Randomized Study Performed by Intergruppo Italiano Linfomi (IIL).. <i>Blood</i> , 2007, 110, 3429-3429.	0.6	1
316	Incidence and Outcome of Myelodysplastic Syndromes in Province of Modena.. <i>Blood</i> , 2007, 110, 4610-4610.	0.6	1
317	The Outcome of T-Cell Lymphoma Patients Failing First-Line Treatment: Results of a Population Based-Study From the Modena Cancer Registry. <i>Blood</i> , 2012, 120, 1611-1611.	0.6	1
318	The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20019-e20019.	0.8	1
319	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
320	Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to mileshkin et al.. <i>British Journal of Haematology</i> , 2003, 123, 748-748.	1.2	0
321	Reply: An inverse association between tumour size and overdiagnosis may explain the results by Bucchi et al. <i>British Journal of Cancer</i> , 2005, 92, 1815-1816.	2.9	0
322	The role of anthracyclines in follicular lymphomas. <i>Leukemia and Lymphoma</i> , 2006, 47, 2267-2268.	0.6	0
323	Editorial from Guest Editor [Hot Topic: Familial and Hereditary Breast and Ovarian Tumors (Guest) Tj ETQq1 1 0.784314 rgBT /Overlook	0.1	0
324	Reply to R.L. Olin et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 3609-3610.	0.8	0

#	ARTICLE	IF	CITATIONS
325	A Predictive Model for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Retrospective Analysis of 1,252 Cases Performed by the Intergruppo Italiano Linfomi (IIL).. Blood, 2004, 104, 3261-3261.	0.6	0
326	Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSC Trial.. Blood, 2006, 108, 2475-2475.	0.6	0
327	Incidence, Clinical Characteristics and Survival of Malignant Lymphomas in the Province of Modena (Italy); a Population-Based Study.. Blood, 2006, 108, 4628-4628.	0.6	0
328	International T-Cell Lymphoma Classification Project: Angioimmunoblastic T-Cell Lymphoma.. Blood, 2006, 108, 2052-2052.	0.6	0
329	Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.. Blood, 2006, 108, 2763-2763.	0.6	0
330	Incidence and Outcome of Chronic Myeloproliferative Disorders: A Population-Based Study from a Cancer Registry in Northern Italy.. Blood, 2007, 110, 4650-4650.	0.6	0
331	Primary Thyroid Lymphoma: A Retrospective IELSG and IIL Analysis of Clinical Characteristics, Prognostic Factors, Treatment Outcome and Somatic Hypermutation for Localized Diffuse Large B-Cell Lymphoma (DLBCL).. Blood, 2007, 110, 3432-3432.	0.6	0
332	Secondary Malignancies after Treatment of Aggressive Non-Hodgkin Lymphoma: A GISL Cohort Study on 1259 Patients.. Blood, 2007, 110, 522-522.	0.6	0
333	Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers.. Blood, 2008, 112, 1061-1061.	0.6	0
334	Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group. Blood, 2010, 116, 2423-2423.	0.6	0
335	Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY. Blood, 2011, 118, 2837-2837.	0.6	0
336	The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2651-2651.	0.6	0
337	Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2636-2636.	0.6	0
338	BOTH MD Anderson Cancer Center MODEL and German Score Work in Predicting Time to First Treatment in EARLY Chronic Lymphocytic Leukemia: Results of an External Validation Analysis. Blood, 2012, 120, 3934-3934.	0.6	0
339	What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study "Refol" by the Fondazione Italiana Linfomi (FIL) On 548 Patients. Blood, 2012, 120, 154-154.	0.6	0
340	Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ®) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970). Blood, 2012, 120, 3644-3644.	0.6	0
341	Monocytosis Has Adverse Prognostic Significance and Impacts Survival in Patients with T-Cell Lymphomas.. Blood, 2012, 120, 2647-2647.	0.6	0
342	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 3653-3653.	0.6	0

#	ARTICLE	IF	CITATIONS
343	NF10 Project: An International, Prospective, Observational Study Of Patients With Indolent Non-Follicular Lymphoma. Analysis Of First 215 Patients. <i>Blood</i> , 2013, 122, 1782-1782.	0.6	0
344	A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 9641-9641.	0.8	0
345	Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8530-8530.	0.8	0
346	Treatment of Advanced-Stage Hodgkin Lymphoma. <i>Hematologic Malignancies</i> , 2015, , 235-250.	0.2	0
347	European Union (EU) vs. non-EU (NOEU) countries study compliance: the experience of the phase III FLORENCE study testing febuxostat in the Tumor Lysis Syndrome (TLS) prevention.. <i>Journal of Clinical Oncology</i> , 2015, 33, e20677-e20677.	0.8	0
348	Baseline Metabolic Tumour Volume Predicts Outcome in High Tumor Burden Follicular Lymphoma. A Pooled Analysis of Three Multicenter Studies. <i>Blood</i> , 2015, 126, 3919-3919.	0.6	0
349	Neutrophil - Lymphocyte Ratio (NLR) at Diagnosis Is an Independent Prognostic Factor in Patients with Nodular Sclerosis Hodgkin Lymphoma: Results of a Large Multicenter Study Involving 990 Patients. <i>Blood</i> , 2015, 126, 3862-3862.	0.6	0
350	Reply to M. Shibusawa et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200177.	0.8	0
351	Estimates of cancer burden in Emilia-Romagna. <i>Tumori</i> , 2013, 99, 327-33.	0.6	0